M617

Product Name:M617

CAS No:860790-38-1

Purity:95%

Molar Mass:2361.68

Chemical Formula:C112H161N29O28

Storage:Store at -20 degrees Celsius

Sequence:GWTLNSAGYLLGPQPPGFSPFR

Target:GAL1

Application:

M617 is a compound associated with GAL1 (galanin receptor 1), which is one of the receptors for the neuropeptide galanin. GAL1 plays a crucial role in regulating various physiological processes such as pain modulation, mood regulation, feeding behavior, and neuroprotection. By targeting the GAL1 receptor, M617 is utilized in research to explore galanin signaling pathways and their implications in neuropsychiatric disorders, pain control, and metabolic functions. It is a valuable tool for studying the therapeutic potential of modulating galanin receptors in conditions like anxiety, depression, and neuropathic pain.

Current Research:

M617, identified by CAS number 860790-38-1, is a synthetic peptide and a selective agonist for the galanin receptor subtype 1 (GAL1). It demonstrates high binding affinity for GAL1, with a Ki value of 0.23 nM, while showing significantly lower affinity for GAL2 (Ki = 5.71 nM). This specificity makes M617 a valuable tool for studying GAL1-mediated signaling pathways and their physiological and pathological implications.
In diabetes research, M617 has been investigated for its role in cardiac glucose metabolism. Studies in type 2 diabetic rat models have shown that central administration of M617 enhances the expression of glucose transporter type 4 (GLUT4) in cardiac tissue, leading to improved glucose uptake and cardiac function. These findings underscore its potential as a therapeutic agent for addressing glucose dysregulation and its cardiovascular complications.
M617 also exhibits promising effects in pain management. By targeting GAL1 receptors, it has been shown to exert significant antinociceptive effects in inflammatory pain models. These results suggest its potential use in developing therapies for chronic and inflammatory pain conditions, particularly where conventional treatments may be insufficient.
Beyond its therapeutic implications, M617 is a critical tool for research into the galaninergic system. Its high selectivity and potency allow researchers to investigate the specific roles of GAL1 receptors in diverse biological processes, including energy metabolism, pain modulation, and neuroprotection. Additionally, it serves as a reference compound for developing novel GAL1-targeted drugs.
As research into the galaninergic system expands, M617 remains at the forefront of studies exploring the therapeutic potential of GAL1 modulation. Its utility in preclinical studies highlights its importance in advancing our understanding of GAL1 receptor biology and its application in treating metabolic and neurological disorders.

Reference:

Fu, L. B., Wang, X. B., Jiao, S., Wu, X., & Yu, L. C. (2011). Antinociceptive effects of intracerebroventricular injection of the galanin receptor 1 agonist M 617 in rats. Neuroscience letters, 491(3), 174-176.